Navigation Links
Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President
Date:11/24/2008

ANN ARBOR, Mich., Nov. 24 /PRNewswire/ -- Terumo Heart, Inc. is pleased to announce the appointment of William Pinon to the position of Chief Executive Officer (C.E.O.) and President, effective immediately. "With its innovative mag-lev technology, Terumo Heart is positioned for a strong leadership role in the future treatment of heart failure. I am excited to lead the acceleration of enrollment in the DuraHeart U.S. Pivotal trials in up to 40 clinical sites, and further capitalize on the commercial potential for DuraHeart's CE Mark in Europe," Mr. Pinon commented. Chisato Nojiri, M.D. Ph.D. will continue to serve as Chairperson of the Board and Chief Medical Officer of Terumo Heart, Inc. Dr. Nojiri has been instrumental in bringing the product from its very early development phase through commercialization in Europe, to the start of the U.S. Pivotal Clinical Trial and recent completion of the Japanese Clinical Trial patient enrollment. Dr. Nojiri will continue her global clinical and scientific focus and leadership.

"With the expansion of our U.S. clinical sites, Terumo Heart is experiencing rapid growth. Mr. Pinon's proven track record in the cardiovascular industry and extensive sales and operational experience, are ideally suited to lead our commercialization efforts in the U.S. and continued growth in Europe," said Dr. Nojiri.

Most recently, Mr. Pinon was C.E.O. of Bioheart, a biotechnology company focused on the development of heart failure therapies and devices. Prior to Bioheart, Mr. Pinon held a variety of positions with Johnson & Johnson including Worldwide Vice President of Sales and Marketing at Cordis Corporation where he oversaw the cardiovascular business including the market leading drug eluting stent, CYPHER (TM). Mr. Pinon received a bachelor's degree in biology from the University of Oregon.

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe.


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. ATS Medical Expands Open Pivot Heart Valve Offerings
4. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
5. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
6. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
9. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
10. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
11. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
Breaking Biology News(10 mins):